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 35 
Abstract 
 
The factors responsible for the low detection rate of cell-free tumor DNA 
(ctDNA) in the plasma of glioblastoma (GB) patients are currently unknown. In 
this study, we measured circulating nucleic acids in patient-derived 40 
orthotopically implanted xenograft (PDOX) models of GB (n=64) and show 
that tumor size and cell proliferation, but not the integrity of the blood-brain 
barrier or cell death, affect the release of ctDNA in treatment naïve GB PDOX. 
Analysis of fragment length profiles by shallow genome-wide sequencing 
(<0.2x coverage) of host (rat) and tumor (human) circulating DNA identified a 45 
peak at 145 bp in the human DNA fragments, indicating a difference in the 
origin or processing of the ctDNA. The concentration of ctDNA correlated with 
cell death only after treatment with Temozolomide and radiotherapy. Digital 
PCR detection of plasma tumor mitochondrial DNA (tmtDNA), an alternative 
to detection of nuclear ctDNA, improved plasma DNA detection rate (82% 50 
versus 24%) and allowed detection in cerebrospinal fluid (CSF) and urine.  
Mitochondrial mutations are prevalent across all cancers and can be detected 
with high sensitivity, at low cost and without prior knowledge of tumor 
mutations via capture-panel sequencing.  Coupled with the observation that 
mitochondrial copy number increases in glioma, these data suggest analyzing 55 
tmtDNA as a more sensitive method to detect and monitor tumor burden in 
cancer, specifically in GB where current methods have largely failed. 
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Introduction 70 
 
Release of DNA fragments from solid tumors, which can be collected in body 
fluids and used to identify and quantify tumor mutations, has created new 
possibilities for minimally invasive diagnosis and therapy monitoring (1,2). The 
concentration of cell-free tumor DNA (ctDNA) varies with cancer type, with 75 
some, such as glioblastoma (GB), showing extremely low plasma 
concentrations (3), which has hindered clinical translation.  
 
Although ctDNA levels have been correlated with tumor burden (2,4) an 
understanding of the relationship between tumor biology and the release of 80 
ctDNA into the circulation is lacking, most notably for GB. Detection and 
measurement of ctDNA may be affected by both technical and biological 
factors (1,5). Recent work has related necrosis, tumor volume and 
proliferation to detection of ctDNA in patients with non-small cell lung cancer 
(2). However, no investigation of the effect of tumor biology on ctDNA release 85 
in GB has been performed.  
 
Using a large cohort of patient derived orthotopically implanted xenografts 
(PDOX) (n=64) we investigated combined detection of circulating tumor 
mitochondrial DNA (tmtDNA) and ctDNA. Custom digital PCR (dPCR) was 90 
used to differentiate human mitochondrial DNA, originating from grafted tumor 
cells, from the host rat mitochondrial DNA. We demonstrated a higher 
frequency of detection and higher copy number for tmtDNA when compared 
with ctDNA in the plasma, cerebrospinal fluid (CSF) and urine of the 
xenografted rats. We used this improved yield to analyze the factors affecting 95 
tumor DNA release. 
 
Release of ctDNA and tmtDNA in treatment naïve GB was associated with 
tumor volume and cell proliferation but not cell death.  However, following 
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treatment with Temozolomide and radiotherapy (6), plasma tmtDNA was 100 
correlated with the levels of tumor cell death. Finally, bypassing blood brain 
barrier (BBB) integrity did not significantly affect the yield of ctDNA or tmtDNA. 
 
Materials and Methods 
 105 
Cell culture 
Cells were obtained either locally or from the American Type Culture 
Collection (ATCC, Manassas, Virginia, US) and mycoplasma tested using 
RNA-capture ELISA. Cell line authentication was performed using STR 
genotyping contemporaneously with the experiments. U87 cells (ATCC) were 110 
cultured in Dulbecco’s modified Eagle’s medium, 2 mM L-glutamine (Gibco, 
UK) and 10% fetal bovine serum (Gibco, UK). Patient-derived cell lines were 
derived using protocols compliant with the UK Human Tissue Act 2004 (HTA 
licence ref. 12315), approved by the Local Regional Ethics Committee 
(LREC ref. 04/Q0108/60) and in accordance with the Declaration of Helsinki. 115 
GB tissue was minced and cells filtered (40 μm) (Falcon, UK) and washed 
with red blood cell lysis buffer. Live cells were seeded at 1.5 x 104 cm2 and 
grown as monolayer cultures on extracellular matrix (ECM)-coated flasks 
(Engelbreth-Holm-Swarm murine sarcoma – 1:10 dilution, Sigma, UK) in 
Neurobasal A (Gibco, UK), 2 mM L-glutamine (Sigma, UK), 1% 120 
Streptomycin/Penicillin/Amphotericin B (Invitrogen, UK), 20 ng/mL hEGF 
(Sigma, UK), 20 ng/mL hFGF (R&D systems, UK), 2% B27 (Invitrogen, UK) 
and 1% N2 (Invitrogen, UK) at 37.5°C in 5% CO2.. 
 
Orthotopic tumor model  125 
Procedures were performed in compliance with project and personal licenses 
issued under the United Kingdom Animals (Scientific Procedures) Act, 1986, 
and approved by the local Animal Welfare and Ethical Review Body. Patient-
derived cells, below passage 20, were re-suspended at 2 x 105 cells μL-1 and 
5 μL were implanted stereotactically (2 mm anterior and 3 mm lateral to the 130 
bregma (right-side)) in 6 week-old female rnu/rnu athymic nude rats (Charles 
River, Germany; Harlan, UK) (n=64).   
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Subcutaneous tumor model  
Patient-derived cells (GB4) were re-suspended at 2.5 x 104 cells μL-1 and 200 135 
μl injected subcutaneously into the right flank of 6 athymic nude rats.  
 
Sample collection 
Whole blood was taken via tail vein cannulation or peri-mortem via cardiac 
puncture and exsanguination. Coagulation was inhibited by adding 4.5 140 
mmol/L EDTA to a maximum of 6 mL of blood. CSF was collected peri-
mortem via cisterna magna puncture (7) and urine by direct bladder 
cannulation. Samples were centrifuged (4°C,1500 x g for 10 mins then 20,000 
x g for 10 mins) before freezing (-80 °C). 
 145 
DNA extraction 
DNA from plasma (~1 mL), CSF (~100 μL), and urine (~100 μL) was extracted 
with the QIAamp Circulating Nucleic Acids kit (QIAGEN), elution volume 50 
µL.  Fragments of the Xenopus Tropicalis genome were spiked into the 
samples to estimate DNA extraction efficiency (Forward PCR primer - 5’-150 
GTGATCATGGGATTTGTAGCTGTT - 3’; Reverse PCR primer – 5’ 
AAACCAACCTGAAAACCATGGA - 3’). 
 
Western blot 
Cell or tissue samples were lysed in RIPA buffer with 1% protease inhibitor 155 
(Thermo Fisher, Waltham, MA, US), run on BIS-TRIS gels (Thermo Fisher) 
transferred onto nitrocellulose membranes and incubated with nestin (Atlas, 
Stockholm, Sweden 1:100) and β-Actin (Abcam, 1:5000) antibodies in Li-
COR-Odyssey blocking buffer (Li-COR Biotechnology, Lincoln, NE, US) 
overnight at 4°C.  Primary antibodies were visualized using fluorescently-160 
labeled anti-mouse or anti-rabbit Li-COR secondary antibodies and a LI-COR 
Odyssey CLx imaging system (LI-COR biotechnology, Lincoln, NE, US). 
 
Chemoradiation  
Rats were anesthetized with 1-2% isoflurane (Isoflo, Abbotts Laboratories 165 
Ltd., UK) and tumors irradiated via a lead collimator (15 Gy; Cs-137 irradiator 
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(IBL 637; CIS Bio International, France). Temozolomide (100 mg kg-1 was 
given by oral gavage 1 hour prior to radiotherapy. 
 
 170 
 
Histopathology and Immunohistochemistry 
Brains were placed in 10% formalin (Sigma-Aldrich, St Louis, US) for 24 
hours, and then sectioned. Hematoxylin and eosin staining (H&E) (ST020 
Multistainer – Leica Microsystems, Germany) was performed on 5 μm 175 
sections. TUNEL staining and immunohistochemistry (IHC) were performed 
on 10 μm sections. TUNEL staining used Leica’s Polymer Kit (Leica 
Microsystems, Germany) and Promega’s DeadEnd Colorimetric TUNEL 
System (Promega, US). IHC was performed using Leica’s Polymer Refine Kit 
and human-specific antibodies: Ki67 – 1:200 dilution (M7240, Dako, Espoo, 180 
Finland), cleaved caspase 3 (CC3) – 1:200 dilution (9664, Cell Signalling 
Technology, Danvers, US), Glial Fibrillary Acid Protein (GFAP) – 1:10,000 
dilution (Z0334, Dako, Espoo, Finland) and Carbonic Anhydrase 9 (CAIX) – 
1:1000 dilution (AB1001, BioScience, Slovakia). 
 185 
In situ hybridisation 
Pecam1 (CD31) mRNA was detected on 5 μm FFPE tissue sections with a 
probe for rat Pecam1 (NM_031591.1, region 861 – 1766; RNAscope 2.5 LS 
red detection kit, 322150, Advanced Cell Diagnostics, USA) on a Leica Bond 
Rx (Leica Biosystems, Melbourne, Australia). Hybridization was detected 190 
using the Bond Polymer Refine Red detection kit (Leica Biosystems, DS9390) 
followed by counterstaining with haematoxylin. Probes targeting peptidylprolyl 
isomerase B (PPIB) (NM_022536.2, region 95 – 830) and Dabp (EF191515, 
region 414 – 86) were used as positive and negative controls, respectively. 
 195 
Image analysis 
Images, were annotated manually and analyzed using in-house algorithms 
(Aperio, Leica) 
 
Digital PCR 200 
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Digital PCR was performed using Fluidigm 12.765 and 37k dPCR chips 
(Fluidigm, US). For targeting human nuclear DNA: 5 µl of TaqMan Gene 
Expression Master Mix, 0.5 µl of buffer, 0.5 µl of EVAGREEN (Biotium, 
Hayward, CA, US) and 1 µl of 10 µM forward primer (5’-
TCACTCAAAGCCGCTCAACTAC-3’) (Invitrogen, US) and 10 µM reverse 205 
primer (5’-TCTGCCTTCATTTCGTTATGTACC-3‘) (Invitrogen, US) were 
mixed with 3.5 µl of DNA. Primers for identifying human mitochondrial DNA 
were: forward 5’-ATACCCATGGCCAACCTCCT-3’, reverse 5’-
GGGCCTTTGCGTAGTTGTAT-3’. Primers for identifying rat DNA were: 
forward 5’-CCACCCCCTGGGCTCTGTT-3’, reverse 5’-210 
CCCGGATCCCCTGCGTGAGA-3’. Assays for human DNA (ctDNA) and rat 
DNA (non-tumor cell-free DNA (nt cfDNA)) targeted the human (RPP30 gene) 
and rat (RPP30 gene) sequences, respectively, in copy number neutral 
regions where there was no homology with the reciprocal rat and human 
genomes.  215 
 
Shallow whole genome sequencing 
Libraries were prepared using a NEB ultra v2 kit (New England Biolabs, 
Ipswich, US). Ten ng of tumor issue DNA was sheared to 150 – 200 bp with 
an ultra-sonicator (Covaris, Woburn, US). For plasma and CSF samples, we 220 
selected rats with concentrations of ctDNA greater than 1000 copies/mL, as 
determined by dPCR. Libraries were pooled in equimolar amounts and 
sequenced on a HiSeq 2500 (Illumina, San Diego, US) generating 125 bp 
paired-end reads. Reads were aligned and localization of somatic copy 
number aberrations was estimated by QDNAseq (8). 225 
 
Magnetic Resonance Imaging 
We used a 7T spectrometer (Agilent, Palo Alto, US) and a 72 mm inner-
diameter 1H quadrature birdcage coil (Rapid Biomedical GMBH, Rimpar, 
Germany). Animals were anesthetized with 1-2% isoflurane in O2.   Axial T2-230 
weighted images were acquired using a fast spin-echo sequence (TR, 1.5 s; 
TE, 40 ms; 256 x 256 data points over a 40 x 40 mm field-of-view (FOV), 4-8 
averages) from fifteen 2 mm thick slices. A T1-weighted spoiled gradient echo 
sequence (27 flip angle, TR 43 ms, TE 4.6 ms, FOV 40 mm x 40 mm, 256 x 
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128 data points) was used to acquire images before and 30, 60 and 90 s after 235 
injection of contrast agent (100 μmol/kg Dotarem; Guebert).  Five axial slices, 
1.5 mm thick and with a 0.3 mm gap between them were acquired.  Images 
were transferred to MATLAB (The Mathworks, Natick, USA) and difference 
maps calculated, on a voxel-by-voxel basis, as the post contrast image minus 
the pre-contrast image divided by the pre-contrast image. 240 
 
Disruption of the blood brain barrier  
Mannitol (2-2.5 mL of a 25% solution in 0.9% saline) was administered via a 
tail vein cannula. Rats immediately underwent diuresis, evident from urinary 
incontinence under anesthesia. 245 
 
Demonstration of blood-brain barrier opening using dynamic contrast-
enhanced magnetic resonance imaging 
Images were acquired using the 72 mm diameter 1H transmit coil and a 2-
channel rat-head 1H receiver coil placed over the brain. A fast spin-echo 250 
sequence (TR 2 s, TE 48 ms, FOV 4 cm x 4 cm, 2 mm thick slice, 256 x 256 
data points) was used to acquire 4 axial brain slices from the same region 
where tumors were implanted in the other animals. Baseline T1 
measurements used an inversion recovery-spoiled gradient echo sequence 
(adiabatic inversion pulse, 8 inversion times between 0.05-10 s, scan repeat 255 
time 12 s, TR 2.08 ms, TE 0.92 ms, flip angle 10°, 4 x 1.8 mm thick slices with 
a 0.2 mm gap between slices). Dynamic contrast enhanced (DCE) images 
were acquired using a gradient echo sequence (TR 25 ms, TE 2.85 ms, flip 
angle 30°).  A series of 100 images (2 averages, 6.4 s per set of 4 images) 
were acquired. Dotarem (0.2 mmol/kg; Gadoteric acid, Guerbet, France) was 260 
injected via a tail vein after the 10th time point image.  Mannitol was 
administered immediately prior to the start of DCE image acquisition. Signals 
from the DCE time course were converted, on a pixel-by-pixel basis, to a 
contrast-agent concentration by assuming an R1 relaxivity for Dotarem of 3.1 
s-1mM-1 (9). An elliptical region of interest was drawn in each of the four slices, 265 
covering the thalamus to the pre-frontal cortex and an average DCE profile 
was calculated (10) using the same population-derived double-exponential 
arterial-input-function for each data-set (11).  The calculated extravascular 
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and extracellular spaces per unit volume of tissue (Ve) accessible to the 
contrast agent were used as an indicator of blood brain barrier permeability.  270 
 
 
Statistics 
Statistics were performed using GraphPad Prism (GraphPad Software Inc, 
California, US) and R (www.r-project.org). Principal Component Analysis 275 
(PCA) was performed with R using the factoextra package. 
 
Results 
 
tmtDNA is a more sensitive marker of systemic tumor nucleic acids than 280 
ctDNA and is detected in multiple body fluids. 
 
There are 102 - 105 copies of the 16.5 kb mitochondrial genome per human 
cancer cell (12) and therefore tmtDNA released into the circulation may be a 
more sensitive marker of tumor burden than ctDNA (13). We used dPCR to 285 
investigate the levels of tmtDNA and ctDNA in different rat PDOX models of 
GB, which were derived from tumor material taken from different GB patients.  
The selected dPCR assays were chosen from among 9 dPCR assays. 
Specificity for human (in the PDOX models this represents tumor DNA) and 
rat (host) DNA was determined using plasma DNA from 4 healthy human 290 
individuals and 4 non-grafted rat controls (Fig. 1a). Human nuclear DNA 
levels averaged 7469 copies/mL and human mitochondrial DNA averaged 
38091 copies/mL in the human plasma samples, where copies/mL represents 
the number of amplifiable copies in the dPCR reaction.  Rat nuclear DNA was 
not detected in the human plasma and human nuclear DNA was not detected 295 
in rat plasma, despite a high concentration of rat nuclear DNA (15610 
copies/mL). Only very low amounts of human mitochondrial DNA (mean 3 
copies/mL, <0.02%) were detected in rat plasma.  
 
The sensitivity of our selected ctDNA and tmtDNA assays were determined 300 
with a duplicate dilution series of human DNA in rat plasma DNA.  The 
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tmtDNA assay could detect the presence of human DNA at dilution levels 
100x greater than the ctDNA assay, and could detect the presence of human 
mitochondrial DNA even when human nuclear DNA could no longer be 
detected (Fig. 1b).  305 
 
Six representative PDOX models of GB (GB1, 8 rats; GB2, 8 rats; GB3, 3 
rats; GB4, 36 rats; GB5, 6 rats and GB6, 3 rats) were studied. In total 64 
animals were analyzed using the dPCR assay. As shown previously (14) 
these models showed much slower growth rates than tumors arising from 310 
implantation of a GB cell line (U87) (Supplementary Fig. S1a and 
Supplementary Table 1) and much higher levels of expression of glial 
fibrillary acidic protein in vivo (15) (Supplementary Fig. S1b) and nestin, a 
neural stem cell marker, in vitro (16), which were largely absent from U87 
tumors and cells respectively (Supplementary Fig. S1c). All showed 315 
histological features of GB (Supplementary Fig. S1d). 
 
Plasma ctDNA was detected in all but one cohort (GB1), with a detection rate 
of 24% across all animals (15/64) and at an average concentration of 27 
tumor haploid genome equivalents per mL (copies/mL of the targeted human 320 
sequence) (Fig. 2a, b). Plasma tmtDNA was identified in all the PDOX 
cohorts with a detection rate of 82% (52/64) and an average concentration of 
5081 copies/mL (~190-fold higher than the mean value for ctDNA) (Fig. 2a, 
b). Non-tumor (rat host) cell-free nuclear DNA was detected in all the animals 
at considerably higher concentrations than ctDNA (t-test, p<0.001) with a 325 
mean concentration of 6989 copies/mL (Fig. 2a, b). Variable detection rates 
were observed between the different PDOX models, with tmtDNA detected in 
66% of some models (GB1; n = 8) and 100% in others (GB5; n = 6) 
(Supplementary Fig. S2a). ctDNA and tmtDNA were not detected in plasma 
from non-grafted animals (n=4), (Supplementary Fig. S2b). 330 
 
ctDNA has been detected at low concentrations in urine from patients with 
non-brain tumors (17). Urine samples from 11 tumor-bearing animals (10 GB4 
and 1 GB5) had undetectable levels of ctDNA. However, tmtDNA was 
identified in 60% of samples with a median concentration of 606 copies/mL 335 
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(Figure 2c, d). The CSF presents another possible source of cell-free tumor 
DNA. We collected an average of 97 μL of CSF (7) from 12 PDOXs (10 GB4, 
1 GB1 and 1GB2). ctDNA was detected in 4 out of 12 samples (median 
concentration of 222 copies/mL) and tmtDNA was detected in all samples 
(median concentration of 760 copies/mL) (Fig. 2c, d). Rat host cell-free 340 
nuclear DNA was detected in all samples with a median concentration of 215 
copies/mL. 
 
ctDNA and tmtDNA levels correlate with tumor size and cell proliferation in 
treatment naïve PDOXs 345 
 
We performed principal component analysis (PCA) on 8 tumor-related 
variables in treatment naïve GB4 models (n=36). The first component 
included plasma ctDNA and tmtDNA concentrations, tumor volume and Ki67 
staining, a marker of cell proliferation, and the second component the plasma 350 
concentration of host non-tumor cell-free nuclear DNA (nt cfDNA), staining for 
TUNEL and cleaved caspase 3 (CC3), which are cell death markers, and 
carbonic anhydrase 9 (CAIX), a marker of hypoxia (Fig. 3). Correlations 
(Pearson analysis) were observed between tmtDNA and ctDNA (R2=0.83, 
p<0.001), tumor-derived DNA and tumor volume (tmtDNA R2=0.86, p<0.001; 355 
ctDNA R2=0.83, p<0.001) and tmtDNA and ctDNA and the number of 
proliferating cells (Ki67 positive cells) (tmtDNA R2=0.54, p<0.001, ctDNA 
R2=0.54, p<0.001). We also observed a correlation between nt cfDNA and cell 
death (TUNEL R2=0.62, p<0.001 and CC3 R2=0.47, p<0.01). Tumor 
microvessel density was not significantly different between the different PDOX 360 
models (p=0.27) (Supplementary Fig. S3).  
 
ctDNA and tmtDNA levels correlate with cell death following treatment with 
Temozolomide and radiotherapy 
 365 
In GB4 (n=36) tmtDNA and ctDNA were highly correlated with tumor volume 
(R2=0.8; p=<0.0001) (Fig. 4a), suggesting that tmtDNA, like ctDNA, could be 
used to track tumor burden and monitor treatment response.  
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We analyzed plasma from GB4 PDOX models 72 hours after treatment with 370 
Temozolomide plus radiotherapy (15 Gy, n=7). ctDNA detection frequency 
and concentration increased (from 40%, 7 copies/mL to 75%, 54 copies/mL, 
p=0.051), (Fig. 4b). tmtDNA concentration also increased (from a median 121 
copies/mL to 256 copies/mL, p=0.094), (Fig. 4b) but detection frequency 
remained unchanged (6/7 cases). These increases in ctDNA and tmtDNA 375 
concentrations were associated with an increase in tumor cell death, as 
assessed by TUNEL (p=0.039) (Fig. 4c) and CC3 staining (p=0.037) of tumor 
sections (n=7) (Fig. 4d), with a correlation being observed between ctDNA 
and CC3 staining (R2=0.58, p=0.074, Pearson analysis), which is a marker of 
early apoptosis (18).  380 
 
These data indicate that in treatment naïve models, tumor DNA release was 
related to tumor burden and cell proliferation, whereas following treatment, 
tumor DNA was released primarily through tumor cell death.  
 385 
Genome-wide sequencing showed a different fragmentation pattern for ctDNA 
and host DNA in treatment naïve PDOXs 
 
We used genome-wide sequencing at low coverage (<0.2x) to determine 
copy-number profiles of host rat and human (tumor) nuclear genomes in 390 
plasma, CSF and tumor tissue. Paired-end sequencing reads were aligned to 
rat (RGSC 6.0 / rn6) and human (hg19) genomes, and assigned to the 
appropriate species (Fig. 5a). Similar copy number profiles were found in 
tumor DNA from the different fluid compartments and from tumor tissue (Fig. 
5b), even though the plasma compartment exhibited a lower tumor DNA 395 
fraction, relative to host DNA, when compared with tumor tissue and CSF. We 
also determined the size distribution of human (tumor) and rat (host) 
circulating nuclear DNA fragments (Fig. 5c-e) in the plasma of animals 
grafted with GB6 (Fig. 5c) and with GB4 (Fig. 5d). We also determined, for 
one animal implanted with GB4, the size distribution of the DNA fragments 400 
from CSF (Fig. 5e). The fragment size distribution in plasma and CSF showed 
a peak at 133-145 bp for human (tumor) DNA, and a different fragmentation 
pattern for host rat DNA, with a peak at 167 bp (Fig. 5c-d). Mitochondrial DNA 
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showed a peak below 100 bp for both human (tumor) and rat circulating 
mitochondrial DNA (Fig. 5f), in agreement with previous work (19). 405 
 
 
The blood-brain barrier has a limited effect on plasma ctDNA and tmtDNA 
concentrations 
 410 
Despite extensive disruption of the BBB during gliomagenesis (20), the low 
levels of ctDNA observed in the plasma of GB patients and the apparent 
enrichment of tumor DNA in the CSF have been attributed to the 
impermeability of the BBB (3). This was supported by sequencing, where 
tumor mutations in DNA from the CSF of GB patients were detected more 415 
frequently than in plasma and at higher mutant allele fractions (21,22). 
However, the absolute concentrations of tumor and non-tumor DNA in CSF 
and in plasma of GB patients have not been reported previously.  The data 
shown in Figure 2 show that the higher detection rate of tumor DNA in CSF is 
due to a higher concentration of ctDNA relative to host nt cfDNA in CSF (222 420 
copies/mL ctDNA versus 215 copies/mL nt cfDNA) when compared to plasma 
(27 copies/mL ctDNA versus 6989 copies/mL nt cfDNA).  We investigated this 
further by using dPCR to quantify the concentrations of tmtDNA in plasma and 
CSF samples collected from 12 of the tumor models (GB1 (n=1), GB2 (n=1), 
GB4 (n=10)). tmtDNA concentration was higher in CSF as compared to 425 
plasma in each of the tumor models (Fig. 6a), with a median of 476 copies/mL 
in CSF and 93 copies/mL in plasma.  However, CSF volume in the rat is ~90 
μL and the plasma volume ~6 mL (23) and therefore the total amount of 
tmtDNA in the plasma (558 copies) is ~13 times higher than in the CSF (43 
copies), showing therefore that the BBB does not prevent significant amounts 430 
of tumor DNA, at least tmtDNA, from reaching the circulation. Whereas the 
concentration of tumor-derived cell-free DNA was 5~8-times higher in CSF 
compared to plasma, the concentration of nt cfDNA was nearly 25 times 
higher in plasma compared to CSF. Therefore, lower detection rates of tumor-
derived DNA in plasma are due, at least in part, to the presence of higher 435 
levels of background host DNA in plasma. 
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To investigate more directly the effect of the BBB on plasma tmtDNA and 
ctDNA concentrations, we used subcutaneous implantation of GB4 cells to 
generate a GB model that was outside the BBB. We also disrupted the BBB 440 
by intravenous administration of mannitol (24). Following mannitol injection, 
sixty minutes were allowed for ctDNA to escape into the circulation before 
plasma collection. If the BBB blocks release of tumor DNA into the circulation, 
then sixty minutes after mannitol injection there should be an increase in 
tumor DNA levels in the circulation, given that maximal BBB opening occurs 5 445 
min following mannitol infusion (24) and the circulating DNA half-life is 16 min 
(25).  Gadolinium-based contrast agents do not cross the intact BBB and are 
used commonly for MR imaging of BBB breakdown in GB (26).  We confirmed 
in 3 control rats that mannitol infusion caused BBB disruption using dynamic 
contrast-enhanced MRI measurements.  Within 10 minutes of mannitol 450 
administration there was an increase in the fraction of tissue accessible to the 
contrast agent (p<0.02) and in the contrast agent concentration (untreated; 
6.3±4.0 μM (SD), post mannitol; 14.8±1.8 μM (SD), p<0.025 (one sided 
Welch’s t-test) (Supplementary Fig. S4a,b). There were no significant 
differences in the concentrations of ctDNA or tmtDNA between the three 455 
groups, after normalization to tumor volume, which was determined using T2-
weighted MRI (orthotopic model) and caliper measurements (subcutaneous 
model) (one-way ANOVA p=0.57 and individual t-tests; n=16) (Fig. 6b). 
Moreover, the tumor volume-corrected concentrations of ctDNA detected in 
animals with subcutaneous GB tumors were much lower than those reported 460 
for animals implanted subcutaneously with other tumor types (27, 28).  
Analysis of CD31 expression (an endothelial cell marker) showed increased 
microvessel density in subcutaneous versus orthotopic tumors (p=0.0173) 
(Fig. 6c), however there was no significant difference in the ctDNA or tmtDNA 
levels (Fig. 6b), suggesting that release from the subcutaneous tumors was 465 
not affected by vascular density. Comparison of ctDNA and tmtDNA 
concentrations in contrast agent enhancing (GB4, GB3) and non-enhancing 
(GB1, GB5) tumors showed no differences in ctDNA (p=0.65) or tmtDNA 
concentrations (p=0.49) between these groups (Fig. 6d). 
 470 
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Discussion 
 475 
Detection of ctDNA in GB patients is challenging because of low plasma 
concentrations (3). Sampling of cerebrospinal fluid (CSF) has been proposed 
as a method for detecting ctDNA in GB (21,22,29), however, lumbar puncture 
is contraindicated in patients with intracerebral space occupying lesions and 
thus routine use of this technique is not clinically feasible (30,31). 480 
Nevertheless, the requirement for minimally invasive techniques that avoid 
repeated biopsies in GB patients remains due to current inadequacies in 
identifying treatment response/escape (32) and the evolving nature of the 
disease during treatment (33-35). We therefore pursued methods to improve 
detection of circulating tumor-derived nucleic acids through the use of PDOX 485 
models of GB and used these methods to identify factors affecting DNA 
release. 
 
Digital PCR was used to estimate plasma tmtDNA and ctDNA concentrations 
in a large number of PDOX models of GB. The detection rate for tmtDNA was 490 
82% in plasma samples (n=64), at an average concentration of 5081 
copies/mL, versus a detection rate for ctDNA of 24%, at an average 
concentration of 27 copies/mL. Host cell-free nuclear DNA concentrations 
have a broad range and the values we report are within the range reported 
previously for animal models (27, 28). tmtDNA was also detected in 60% of 495 
urine samples in which ctDNA was undetectable. Because tmtDNA is highly 
fragmented in plasma (Fig. 5f), in vitro or in silico size selection of fragments 
below 100 bp could be used to sieve tmtDNA from nuclear ctDNA, enriching 
the sample for tmtDNA and further enhancing the sensitivity of detection (36). 
The potential for tmtDNA to be used to detect smaller tumors, either at 500 
diagnosis or at recurrence would be important clinically.  
 
Using both ctDNA and tmtDNA we investigated the factors influencing release 
of tumor-derived nucleic acids into the circulation. The levels of both were 
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correlated with tumor size, in agreement with previous pre-clinical (27,28) and 505 
clinical (3,25) studies. Previous analyses of cell-free DNA fragment sizes in 
plasma showed these to be mostly distributed around 167 bp, 
and multiples thereof, characteristic of caspase-dependant cleavage and 
suggesting that the majority of cell-free DNA originates from apoptosis 
(37,38). In cancer patients, a shortening of cfDNA was observed (39,40), 510 
which could reflect modifications in chromatin organization (41,42). Recent 
work on fetal cell-free DNA suggested that methylation-related chromatin re-
organization can result in shortening of fragment length (38,43).  The first 
comprehensive analysis of the relationship between tumor physiology and 
ctDNA in patients indicated that cell proliferation and tumor volume are more 515 
strongly correlated with ctDNA concentration than cell death (2).  Here we 
have shown, in treatment naïve PDOX models, that there is a correlation 
between non-tumour (host) cell-free DNA levels and cell death. Fragmentation 
analysis showed a distribution centered around 167 bp, consistent with 
release from apoptotic host cells.  We observed a correlation between ctDNA 520 
levels and tumour volume, and to a lesser extent with cell proliferation, but not 
with cell death, as was observed previously (2).  Analysis of ctDNA fragment 
sizes revealed a shift towards shorter fragment sizes, with a distribution 
centred around 145 bp, corresponding to the core nucleosome.  These 
findings suggest that size selection could potentially be used to improve the 525 
yield of ctDNA fragments (36).  
  
The concentrations of plasma ctDNA and tmtDNA were increased following 
Temozolomide and radiotherapy treatment and, in this instance, were related 
to an increase in tumor cell death. However, CC3 and TUNEL staining only 530 
inform upon a proportion of dying cells and not those affected by mitotic 
catastrophe or senescence for example.  In these treated animals there was 
no longer any correlation between plasma levels of ctDNA and tmtDNA and 
cell proliferation. Therefore, it appears that release of tumor DNA pre and post 
treatment occurs via different processes. DNA release via cell death post 535 
treatment, may be explained by the requirement for tumor cells to be in close 
proximity to viable blood vessels, which provide the oxygen necessary for 
radiotherapy-induced tumor cell kill (44). Thus, when these cells die, they do 
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so in a vessel rich microenvironment, and are distinct from dying tumor cells 
in treatment naïve GB, where cell death may occur predominantly in cells with 540 
a poor blood supply.  
 
The BBB has been proposed as the main reason for reduced ctDNA detection 
in GB (21). Our experiments, in which we circumvented the BBB via 
heterotopic tumor engraftment or opened the BBB using mannitol, suggest 545 
that the effect of the BBB on release of tumor-derived DNA into the plasma 
may be less significant than previously thought. Recent studies have shown 
higher relative levels of mutant DNA in CSF compared to plasma of GB 
patients (21,22), which has been interpreted as being due to enrichment of 
tumor DNA in the CSF. Using dPCR to measure absolute concentrations of 550 
tumor and host DNA we found that higher relative levels of tumor DNA in CSF 
resulted primarily from lower concentrations of non-tumor host DNA together 
with more modest increases in the quantity of tumor-derived DNA.  
 
Whilst we used single-copy human mitochondrial sequences to identify 555 
tmtDNA in the PDOX models, this strategy is not directly applicable to a 
human patient. However, mitochondrial mutations are present in the majority 
of cancers, with frequencies depending upon the tumor of origin, and 
mutational ‘hotspot’ regions have been identified (45), suggesting that 
mutated mitochondrial sequences could be used to detect tmtDNA in the clinic 560 
(12). Whole genome sequencing (WGS) has enabled detection of 
mitochondrial DNA variant-allele fractions down to 1% (46), moreover studies 
have shown that certain tumors positively select for non-synonymous 
mitochondrial DNA mutations (47). Although WGS is expensive, the small size 
of the mitochondrial genome means that targeted, and/or capture-sequencing 565 
based methods could provide a more affordable alternative and may enable 
improved sequencing depth (48). Genome-wide or targeted sequencing of the 
tumor tissue DNA obtained at surgery may also permit strategies whereby 
dPCR probes or focused sequencing assays may be employed to track 
tmtDNA mutations in plasma.  570 
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Several cancers have higher mitochondrial copy numbers, thus further 
increasing the probability of detecting tmtDNA (49). Detection of ctDNA in 
IDH1-mutant glioma, for example, has demonstrated limited clinical efficacy 
(3), however the high tmtDNA copy number in these tumors may make 575 
circulating tmtDNA analysis achievable (49). Recent studies have identified 
certain cancers with functional tmtDNA mutations that affect metabolism (46). 
This could be used to target metabolic therapies to tumors with known 
metabolic weaknesses (46). tmtDNA mutations have also been described 
which confer specific chemoresistant properties (50). Thus their monitoring via 580 
serial liquid biopsy may enable therapy modulation, as has been 
demonstrated with the use of ctDNA (4). 
 
In conclusion, release of tmtDNA and ctDNA is correlated with tumor volume 
and tumor cell proliferation in treatment naïve tumors and with tumor cell 585 
death following treatment. The blood brain barrier appears to play only a 
minor role in preventing release of glioma-derived ctDNA into plasma. 
Analysis of circulating tmtDNA can improve the sensitivity of detection of 
tumor DNA in multiple body fluids and may make plasma liquid biopsy 
possible for patients with gliomas, where detection rates for ctDNA have so 590 
far been very low.  
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Figure legends 
 
Figure 1 Validation of the specificity and sensitivity of the ctDNA and 775 
tmtDNA dPCR assays. a) dPCR assays designed to detect ctDNA, tmtDNA 
and non-tumor cell-free (nt cfDNA) were tested with human and rat plasma 
DNA. Samples were tested in quadruplicate for each assay. ND indicates 
non-detectable. b) Dilution series of human (tumor) DNA in rat (non-tumor) 
DNA, which was used to evaluate the sensitivity of tmtDNA detection in 780 
comparison to detection of ctDNA. tmtDNA was detected at 100x greater 
dilution than ctDNA. Each sample was measured in duplicate. 
 
Figure 2 tmtDNA was detected more frequently in plasma than 
ctDNA. a) Detection rates for plasma circulating cell-free tumor DNA (ctDNA), 785 
tumor mitochondrial DNA (tmtDNA) and non-tumor (rat host) cell-free DNA (nt 
cfDNA) in 64 animals implanted orthoptopically with cells derived from tumors 
from 6 different patients. b) Concentration (copies/mL) of circulating nucleic 
acids in the samples where these were detected. ctDNA (c) and tmtDNA 
concentrations (d) in CSF, plasma and urine from the tumor-bearing animals.  790 
In the ratios shown below the plots in (c) and (d) the numerator represents the 
number of samples containing the indicated DNA and the denominator the 
number of samples. 
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Figure 3 Factors affecting the levels of ctDNA and tmtDNA in the 795 
plasma of treatment-naïve tumor-bearing rats. Principal component 
analysis of variables associated with tumor histology and circulating nucleic 
acids in the plasma of rats with GB4 tumors (n=36). The vectors represent 
ctDNA, tmtDNA and non-tumor cfDNA concentrations, tumor volume, tumor 
proliferation (Ki67), hypoxia (CAIX), necrosis (TUNEL) and apoptosis (CC3). 800 
PC1 (44.9%) and PC2 (25.1%) indicate the % variance accounted for by the 
two principal components.   
 
Figure 4 Factors affecting the levels of ctDNA and tmtDNA in the 
plasma of tumor-bearing rats following concomitant Temozolomide and 805 
radiotherapy treatment. a) Correlation between tumor volume and the 
concentrations of ctDNA, tmtDNA and nt cfDNA in the plasma of animals with 
GB4 tumors (n=36) determined by dPCR. b) ctDNA and tmtDNA levels in a 
subset of 7 rats with GB4 tumors that received 15 Gy with concurrent 
temozolomide, and 5 rats with untreated GB4 tumors that were analyzed as 810 
controls (no_RT). Panels c and d show levels of cell death in the tumors of 
these GB4 models determined by TUNEL and CC3 staining. 
 
Figure 5 The fragmentation patterns of plasma DNA in tumor-bearing 
animals. a) Sequencing reads were obtained by paired-end shallow WGS of 815 
plasma DNA and aligned to the human (tumor) and rat (host) genomes. b) 
Copy number profiles obtained from sWGS of DNA from tumor tissue, CSF 
and plasma from the GB4 model (n=3), separated into reads that aligned with 
the human and rat genome. c) Size distribution of DNA fragments of nuclear 
origin from a plasma sample from the GB6 model. ctDNA fragments 820 
originating from tumor cells, aligned to the human genome, are shown in red, 
whereas nt cfDNA fragments from host cells, aligned to the rat genome, are 
shown in blue. A vertical line (at 167 bp) indicates fragment sizes associated 
with nt cfDNA of apoptotic origin. d) Size distribution of the DNA fragments of 
nuclear origin from a plasma sample from a GB4 tumor-bearing animal. e) 825 
Size distribution of the DNA fragments of nuclear origin from a CSF sample 
from a GB4 tumor-bearing animal. f) Size distribution of mitochondrial DNA 
fragments from a plasma sample: tmtDNA originating from tumor cells, 
Research. 
on December 12, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 2, 2018; DOI: 10.1158/0008-5472.CAN-18-0074 
 25 
aligned to the human mitochondrial genome, are shown in purple, and non-
tumor mitochondrial DNA, aligned to the rat genome, are shown in green. 830 
 
Figure 6 The integrity of the blood brain barrier has little effect on 
ctDNA and tmtDNA levels in plasma. a) Pairwise comparison of tmtDNA in 
plasma and CSF collected at the same time from 10 GB4 tumor-bearing 
animals and two U87 tumor-bearing animals. Concentrations determined in 835 
the CSF are plotted relative to the concentration detected in plasma samples. 
b) Concentrations of ctDNA and tmtDNA, normalized to tumor volume, in the 
plasma of GB4 tumor-bearing rats, where the tumors were implanted 
orthotopically (n=5), with or without disruption of the BBB by mannitol injection 
(n=6), or where the tumors were implanted subcutaneously (n=5). There were 840 
no significant differences in the concentrations of ctDNA or tmtDNA between 
these groups (ANOVA p=0.57 and individual paired t-tests (p>0.2); n=16). c) 
Microvessel density in each tumor model (n=3 per cohort), as analyzed by in 
situ hybridization with a CD31 mRNA probe. d) Plasma ctDNA and tmtDNA 
concentrations in animal models with tumors that showed signal enhancement 845 
(n=22; GB1,3,4), and those that did not enhance (n=18; GB1,2,3,4), in T1-
weighted MR images following administration of a gadolinium-based contrast 
agent. There was no significant difference between the groups (p=0.26). 
Additional points represent outliers. 
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